Johnson & Johnson (NYSE:JNJ) Stake Decreased by Aufman Associates Inc

Aufman Associates Inc decreased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,577 shares of the company’s stock after selling 66 shares during the period. Johnson & Johnson accounts for about 0.6% of Aufman Associates Inc’s investment portfolio, making the stock its 14th largest holding. Aufman Associates Inc’s holdings in Johnson & Johnson were worth $635,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P increased its holdings in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after buying an additional 82,429 shares in the last quarter. IFM Investors Pty Ltd increased its holdings in shares of Johnson & Johnson by 20.1% in the first quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock valued at $74,259,000 after buying an additional 70,221 shares in the last quarter. Essex LLC increased its holdings in shares of Johnson & Johnson by 3.7% in the first quarter. Essex LLC now owns 32,274 shares of the company’s stock valued at $5,720,000 after buying an additional 1,146 shares in the last quarter. Finally, Hardy Reed LLC increased its holdings in shares of Johnson & Johnson by 2.7% in the first quarter. Hardy Reed LLC now owns 5,098 shares of the company’s stock valued at $904,000 after buying an additional 133 shares in the last quarter. Institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Trading Up 0.8 %

Johnson & Johnson stock opened at $176.20 on Friday. The company’s fifty day simple moving average is $167.84 and its 200-day simple moving average is $171.35. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The stock has a market cap of $460.67 billion, a P/E ratio of 24.54, a P/E/G ratio of 3.47 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the company posted $2.60 EPS. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson announced that its board has initiated a share buyback plan on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Insider Buying and Selling

In related news, insider William Hait sold 15,000 shares of the company’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares in the company, valued at $13,764,485.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Hait sold 15,000 shares of the company’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 118,795 shares of company stock worth $20,230,174. Corporate insiders own 0.35% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. StockNews.com started coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Raymond James lowered their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Citigroup lowered their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “neutral” rating and a $170.00 price objective on the stock. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.